Genitourinary (Issue 2)

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.

Abiraterone acetate in combination with low-dose prednisone (5 mg) significantly lowered PSA levels with a consistent toxicity profile in men with high-risk nonmetastatic castration-resistant prostate cancer.

Multiparametric MRI following a suggestive PSA test or digital rectal exam resulted in a 73% reduction in the need for biopsy.

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association Meeting by Tyler M. Bauman, BS, is bringing the discussion into focus.

Leonard Gomella, MD, professor, Jefferson University, physician, chair, Department of Urology, director, Kimmel Cancer Center Network, discusses results from a study that assessed the corticosteroid-associated adverse events with long-term exposure to low-dose prednisone given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer (mCRPC).

PSA testing utilization decreased by 50% among primary care physicians at Oregon Health & Science University, following a recommendation against screening from the USPSTF.

An exosomal messenger RNA-based urine diagnostic demonstrated high negative predictive value for high-grade prostate cancer.

Ryan Werntz, MD, urologist, Oregon Health and Science University, discusses a study which examined trends in prostate-specific antigen (PSA) utilization in primary care physicians.

Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine, discusses the potential of AR-V7 as a biomarker in early stage castration-resistant prostate cancer (CRPC).